Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones PR...
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye...
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.